Christopher Pieczonka, MD

Articles by Christopher Pieczonka, MD

Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPC

July 26th 2021

Christopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.

Christopher Pieczonka, MD, director of clinical research at Crouse Health

Dr. Pieczonka on the Design of the Phase 3 VERACITY Trial With VERU-111 in mCRPC

ByChristopher Pieczonka, MD

June 15th 2021

Christopher Pieczonka, MD, discusses the design of the phase 3 VERACITY trial studying VERU-111 in patients with metastatic castration-resistant prostate cancer.

Christopher Pieczonka, MD

Articles by Christopher Pieczonka, MD

Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPC

Dr. Pieczonka on the Design of the Phase 3 VERACITY Trial With VERU-111 in mCRPC

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD